Jpmorgan Chase & CO Theravance Biopharma, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 266,879 shares of TBPH stock, worth $2.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

266,879

Previous 259,259 2.94%

Holding current value

$2.43 Million

Previous $2.2 Million 2.14%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Dec 26, 2024	BUY	$7.66 - $10.25 $58,369 - $78,105	7,620 Added 2.94%	266,879 $2.15 Million
Q3 2024 Nov 08, 2024	BUY	$7.66 - $10.25 $58,369 - $78,105	7,620 Added 2.94%	266,879 $2.15 Million
Q2 2024 Dec 26, 2024	SELL	$8.29 - $9.92 $63,169 - $75,590	-7,620 Reduced 2.86%	259,259 $2.2 Million
Q2 2024 Aug 12, 2024	BUY	$8.29 - $9.92 $1.89 Million - $2.27 Million	228,396 Added 740.03%	259,259 $2.2 Million
Q1 2024 Dec 26, 2024	SELL	$8.22 - $11.59 $1.94 Million - $2.74 Million	-236,016 Reduced 88.44%	30,863 $276,000
Q1 2024 May 10, 2024	SELL	$8.22 - $11.59 $108,717 - $153,289	-13,226 Reduced 30.0%	30,863 $276,000
Q4 2023 Dec 26, 2024	SELL	$8.58 - $11.4 $1.91 Million - $2.54 Million	-222,790 Reduced 83.48%	44,089 $495,000
Q4 2023 Feb 12, 2024	SELL	$8.58 - $11.4 $31,068 - $41,279	-3,621 Reduced 7.59%	44,089 $495,000
Q3 2023 Nov 14, 2023	SELL	$8.38 - $10.44 $26,430 - $32,927	-3,154 Reduced 6.2%	47,710 $411,000
Q2 2023 Aug 11, 2023	SELL	$10.16 - $11.92 $1.64 Million - $1.93 Million	-161,663 Reduced 76.07%	50,864 $526,000
Q1 2023 May 18, 2023	BUY	$9.87 - $11.44 $493,736 - $572,274	50,024 Added 30.78%	212,527 $2.31 Million
Q1 2023 May 11, 2023	SELL	$9.87 - $11.44 $506,775 - $587,386	-51,345 Reduced 24.01%	162,503 $1.76 Million
Q4 2022 Feb 13, 2023	BUY	$9.65 - $11.34 $132,542 - $155,754	13,735 Added 6.86%	213,848 $2.4 Million
Q3 2022 Nov 14, 2022	SELL	$8.39 - $10.22 $60,760 - $74,013	-7,242 Reduced 3.49%	200,113 $2.03 Million
Q2 2022 Aug 11, 2022	BUY	$8.41 - $10.34 $286,469 - $352,211	34,063 Added 19.66%	207,355 $1.88 Million
Q1 2022 May 11, 2022	SELL	$8.33 - $12.96 $265,043 - $412,361	-31,818 Reduced 15.51%	173,292 $1.66 Million
Q4 2021 Feb 10, 2022	SELL	$7.42 - $11.05 $208,939 - $311,156	-28,159 Reduced 12.07%	205,110 $2.27 Million
Q3 2021 Nov 12, 2021	BUY	$6.77 - $14.41 $1.58 Million - $3.36 Million	233,269 New	233,269 $1.73 Million

Others Institutions Holding TBPH

# of Institutions

127

Shares Held

47.2M

Call Options Held

200

Put Options Held

12.8K

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $609M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Theravance Biopharma, Inc. Transaction History